Results 241 to 250 of about 74,982 (294)
Some of the next articles are maybe not open access.
Release of N-acetylcysteine and N-acetylcysteine Amide From Contact Lenses
Eye & Contact Lens: Science & Clinical Practice, 2013To investigate the use of contact lenses to release N-acetylcysteine (NAC) and N-acetylcysteine amide (NACA) that have frequently used for the treatment of some eye diseases.Three commercial contact lenses were used: Soflens Multi-Focal, 1-Day ACUVUE TruEye, and Frequency 55.
Atabek Yigit E, Ercal N.
openaire +2 more sources
ADVERSE REACTIONS TO N-ACETYLCYSTEINE
The Lancet, 19841 Clinical details of seven patients who suffered adverse reactions to N-acetylcysteine as Parvolex are documented. 2 Skin testing was carried out to diluted Parvolex, and its individual components N-acetylcysteine and ethylenediaminetetra-acetate, in five reacting patients and five patients who had received Parvolex with no ill-effects.
D N, Bateman +2 more
openaire +3 more sources
The promise of N-acetylcysteine in neuropsychiatry
Trends in Pharmacological Sciences, 2013N-Acetylcysteine (NAC) targets a diverse array of factors germane to the pathophysiology of multiple neuropsychiatric disorders including glutamatergic transmission, the antioxidant glutathione, neurotrophins, apoptosis, mitochondrial function, and inflammatory pathways.
Michael, Berk +3 more
openaire +2 more sources
Pharmacokinetics of N-acetylcysteine in man
European Journal of Clinical Pharmacology, 1986N-Acetylcysteine was given intravenously and as three fast dissolving and one slow-release formulation, on separate occasions, as a single dose of 600 mg to 10 fasting (5 men and 5 women) healthy volunteers. Blood and urine were sampled for the following 12 h. Renal clearance constituted around 30% of total body clearance, which was 0.21 l/h/kg. Volume
L, Borgström, B, Kågedal, O, Paulsen
openaire +2 more sources
N-Acetylcysteine in Chronic Blepharitis
Cornea, 2002To investigate the effects of N-acetylcysteine (NAC) in chronic posterior blepharitis.This was a prospective randomized, controlled study that included 79 eyes of 40 patients with chronic posterior blepharitis. Routine ophthalmologic examination, Schirmer-1 test, fluorescein break-up time (FBUT), and mucous fern tests were carried out during the first ...
Elvan, Yalçin +3 more
openaire +2 more sources
Lipoprotein(a) reduction by N-acetylcysteine
The Lancet, 1991Lipoprotein(a), a complex of low-density lipoprotein linked by disulphide bridges with apo(a), is associated with atherosclerotic disease when present at very high plasma concentrations. In vitro, N-acetylcysteine (NAC) dissociates this complex. In two patients with high Lp(a) levels NAC lowered plasma Lp(a) from 58 to 20 mg/dl and from 59 to 18 mg/dl:
D, Gavish, J L, Breslow
openaire +2 more sources
Hyperthyroidism and N-Acetylcysteine
Journal of the American Medical Directors Association, 2021Seema, Rao, S, Rao
openaire +2 more sources
Clinical Pharmacokinetics of N-Acetylcysteine
Clinical Pharmacokinetics, 1991N-Acetylcysteine is useful as a mucolytic agent for treatment of chronic bronchitis and other pulmonary diseases complicated by the production of viscous mucus. It is also used as an antidote to paracetamol (acetaminophen) poisoning and found to be effective for the prevention of cardiotoxicity by doxorubicin and haemorrhagic cystitis from ...
openaire +2 more sources
N-Acetylcysteine in Kidney Disease
2010Acute kidney injury (AKI) is a frequent complication of contrast administration (contrast-induced nephropathy) and cardiac surgery and is associated with increased short-term and long-term morbidity and mortality. Acute kidney injury is becoming a growing problem in modern cardiovascular medicine, in parallel with the increase in application of ...
G. Marenzi, E. Sisillo, A. Bartorelli
openaire +2 more sources